Search the site
Mingquan Zhang, Ph.D.
Associate
Mingquan’s practice focuses on patent and trademark litigation, including proceedings under the Patented Medicines (Notice of Compliance) Regulations, patent infringement / validity proceedings under the Patent Act, and trademark actions. In addition, Mingquan advises clients on patent issues such as infringement and validity. Prior to law school, Mingquan received a B.Sc. in analytical chemistry and a Ph.D. in bioanalytical chemistry.
Education
- B.Sc., Peking University
- Ph.D., University of Toronto
- J.D., University of Toronto
Bar Admission
- Ontario, 2013
My recent cases
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,861,480; 2,914,999 and 2,985,006 (trifluridine/tipiracil).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,861,480 (trifluridine/tipiracil hydrochloride).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,606,282, 2,967,453, and 3,003,988 (dolutegravir-abacavir-lamivudine).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,606,282 (dolutegravir).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,671,357 (canagliflozin).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,534,024 (canagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,655,212 and 2,705,163 (vortioxetine).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,936,852, 2,485,143, 2,544,621 and 2,781,799 (riociguat)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,440,472, 2,521,885, and 2,803,922 (doxycycline)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,402,894 (saxagliptin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), TMA157,162 (ENERGIZER) and TMA740,338 (ENERGIZER)
Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab)
Patent infringement case regarding Patent Nos. 2,475,076 and 2,522,321 (Hard Wood Floor Panels and Manufacturing)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,366,785 and 2,476,934 (etanercept)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), 157,162 (ENERGIZER) and 740,338 (ENERGIZER)
Patent infringement case regarding Patent No. 2,355,347 (quinapril)
More people
.jpg)
.jpg)
%20(1).png)
.jpg)
%20(1).jpg)
